Legislation roundup: Pharma monopoly and export, and data interface security risk monitoring

August 16, 2024 | BY

Susan Mok

SAMR prohibits monopoly agreements that fix or modify pharmaceutical prices. Export pharmaceuticals commissioned for production from a foreign pharmaceutical manufacturer may not be sold and used in the PRC. Guidelines are provided for the methods of monitoring data interface security risks.

Pharmaceuticals

State Administration for Market Regulation, Anti-Monopoly Guidelines for the Pharmaceuticals Sector (Draft for Comments)

国家市场监督管理总局关于药品领域的反垄断指南 (征求意见稿)

This premium content is reserved for
China Law & Practice Subscribers.

  • A database of over 3,000 essential documents including key PRC legislation translated into English
  • A choice of newsletters to alert you to changes affecting your business including sector specific updates
  • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected]